The discovery of AZD9164, a novel muscarinic M3 antagonist

The optimization of a new series of muscarinic M3 antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.

The optimization of a new series of muscarinic M3 antagonists is described, leading to the identification of AZD9164, which was progressed into the clinic for evaluation of its potential as a treatment for COPD.Figure optionsDownload as PowerPoint slide